Lilly's Retatrutide Clears Two More Phase 3 Trials, Eyes 2027 FDA Filing

Eli Lilly (LLY) announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials of retatrutide, its investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon). Both trials met their primary endpoints. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027.

What the trials showed

TRIUMPH-2 enrolled 1,152 adults with obesity or overweight and type 2 diabetes, a population that historically struggles to lose weight. At 80 weeks, participants on the highest dose (12 mg) lost an average of 49.6 lbs (20.8% of body weight). A1C dropped by up to 1.6 percentage points from a baseline of 7.7%. All three studied doses (4 mg, 9 mg, 12 mg) delivered substantial weight loss and glycemic improvement.

TRIUMPH-3 enrolled 1,949 adults with severe obesity (BMI at least 35) and established cardiovascular disease, with or without type 2 diabetes. At 80 weeks, the 12 mg dose produced an average of 55.8 lbs (22.6%) weight loss. The 9 mg dose achieved 52.7 lbs (21.6%).

The cardiovascular data matters more than the headline

The TRIUMPH-3 biomarker data is what sets retatrutide apart from the dual agonists already on the market. At the highest dose:

• Triglycerides: down 37.0%
• Non-HDL cholesterol: down 16.5%
• Systolic blood pressure: down 9.3 mmHg
• Waist circumference: down 7.5 inches
• hsCRP (inflammation marker): down 51.2%

Major adverse cardiovascular events (MACE-5) occurred less frequently in the retatrutide arm than placebo, with a hazard ratio of 0.82 (95% CI: 0.55 to 1.22). That is not statistically significant, but it is directionally favorable and consistent with the cardiometabolic benefits.

Why the filing delay to Q1 2027

Lilly had previously targeted a 2026 filing. The company now says it needs additional time to complete the Chemistry, Manufacturing, and Controls data package required for the BLA. Retatrutide is a biologic, and the CMC requirements are more demanding than for small molecules like orforglipron (Foundayo).

The delay is about manufacturing data, not clinical concerns. Five Phase 3 trials are now complete, all positive. The clinical package is done.

The competitive picture

Retatrutide is Lilly’s third obesity drug after Zepbound (tirzepatide) and Foundayo (orforglipron). As a triple agonist, it activates glucagon receptors in addition to GIP and GLP-1, which drives additional fat oxidation and liver-specific metabolic effects. The weight loss numbers approach bariatric surgery territory, and the cardiovascular biomarker improvements go beyond what weight loss alone explains.

For context on reading trial press releases, see our guide to interpreting clinical trial data.

What to watch next

1. Q1 2027 BLA submission: The filing timeline depends on CMC completion. Any further delay would push approval into late 2027 or 2028.
2. Cardiovascular outcomes trial: The MACE signal is encouraging but not powered for significance. A dedicated cardiovascular outcomes trial would solidify the case.
3. Competitive positioning: Novo Nordisk’s CagriSema (cagrilintide plus semaglutide) is also in Phase 3. The obesity market is about to get crowded at the top end.

Lilly closed at $1,185.87 on July 22, up modestly on the news. The market had largely priced in positive Phase 3 results, but the cardiovascular biomarker data and the filing timeline clarification give investors something concrete to anchor on.

Source: Lilly press release via PR Newswire

What It Means for the Trade

Five Phase 3 trials, five positives, and a Q1 2027 BLA target — retatrutide is now a timing story, and the timing risk is manufacturing paperwork, not science. The CMC delay is the kind of catalyst shift traders hate because it is opaque: Lilly says the clinical package is complete and the biologics CMC data is the holdup, so the filing date depends on internal manufacturing milestones investors cannot observe. The trade implications are concrete. First, a Q1 2027 filing keeps approval realistically in 2027-2028, meaning Lilly’s near-term obesity growth still runs through Zepbound and Foundayo — retatrutide is the 2028+ earnings driver, not the 2027 one. Second, the TRIUMPH-3 data (22.6% weight loss in severe obesity with established cardiovascular disease) positions retatrutide as the premium-efficacy option at the top of the market, the tier above CagriSema and tirzepatide where bariatric-surgery-adjacent patients sit.

Mechanism and Market Context

Retatrutide triple-agonizes GIP, GLP-1, and glucagon receptors — the glucagon arm is the addition beyond tirzepatide’s dual mechanism, driving fat oxidation, energy expenditure, and liver-specific metabolic effects that plausibly explain why the biomarker improvements outrun weight loss alone: triglycerides down 37%, hsCRP down 51.2%, systolic pressure down 9.3 mmHg. TRIUMPH-2’s type 2 diabetes population losing 20.8% at 80 weeks on the 12 mg dose is a striking result in a cohort where injectable GLP-1s have historically undershot, and the A1C drop of up to 1.6 points from a 7.7% baseline supports a diabetes label alongside the obesity claim. The competitive logic inside Lilly’s own portfolio: Foundayo (oral orforglipron) captures the accessibility tier, Zepbound holds the mass injectable market, retatrutide takes the efficacy ceiling — a deliberate segmentation that lets Lilly compete with itself before Novo or the oral challengers can.

Risks and What Could Go Wrong

1. CMC-driven filing slippage past Q1 2027 would push approval toward late 2028 and hand the efficacy-ceiling narrative to CagriSema’s launch.
2. The glucagon component adds GI and heart-rate class tolerability questions; full safety data at congress presentations will be parsed line by line.
3. The MACE-5 signal is not powered — over-reading it invites a correction when the outcomes trial reads.